OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
EAST RUTHERFORD, N.J., May 01, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2017 financial results will be released on Thursday, May 4, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2017 Earnings Conference Call | ||
| When: | Thursday, May 4, 2017 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-877-876-9177 for U.S. 1-785-424-1666 for International Passcode: 6087850 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. 1-719-457-0820 for International Passcode: 6087850 Available through Thursday, May 11, 2017 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
